0001628280-16-021971.txt : 20161212 0001628280-16-021971.hdr.sgml : 20161212 20161212101030 ACCESSION NUMBER: 0001628280-16-021971 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20161209 FILED AS OF DATE: 20161212 DATE AS OF CHANGE: 20161212 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Bellerophon Therapeutics, Inc. CENTRAL INDEX KEY: 0001600132 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 473116175 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 184 LIBERTY CORNER ROAD, SUITE 302 CITY: WARREN STATE: NJ ZIP: 07059 BUSINESS PHONE: 908-574-4770 MAIL ADDRESS: STREET 1: 184 LIBERTY CORNER ROAD, SUITE 302 CITY: WARREN STATE: NJ ZIP: 07059 FORMER COMPANY: FORMER CONFORMED NAME: Bellerophon Therapeutics LLC DATE OF NAME CHANGE: 20140213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Luehring Jens CENTRAL INDEX KEY: 0001631764 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36845 FILM NUMBER: 162045526 MAIL ADDRESS: STREET 1: C/O LINDE NORTH AMERICA INC. STREET 2: 575 MOUNTAIN AVENUE CITY: MURRAY HILL STATE: NJ ZIP: 07974 4 1 wf-form4_148155541708724.xml FORM 4 X0306 4 2016-12-09 0 0001600132 Bellerophon Therapeutics, Inc. BLPH 0001631764 Luehring Jens C/O LINDE NORTH AMERICA, INC. 200 SOMERSET CORPORATE BLV, SUITE 7000 BRIDGEWATER NJ 08807 1 0 1 0 Common Stock 2016-12-09 4 P 0 20000 0.56 A 39860 D Common Stock 3549804 I See footnote These shares are owned directly by Linde North America, Inc. ("Linde"). Jens Luehring is a director and chief financial officer of Linde. Mr. Luehring disclaims beneficial ownership of all shares held by Linde, except to the extent of his pecuniary interest therein. /s/ Jens Luehring 2016-12-12